ARVN - Arvinas, Inc.
About Arvinas, Inc. (https://www.arvinas.com)
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Noah Berkowitz | Chief Medical Officer | 1964 | $834,887 USD |
| Andrew Saik | Chief Financial Officer & Treasurer | 1969 | $819,563 USD |
| Angela Cacace | Chief Scientific Officer | 1968 | $758,163 USD |
| Randy Teel | CEO, President & Director | 1980 | $711,098 USD |
| Alexander A. Santini | Chief Commercial Officer | 1959 | – |
| David Loomis | Vice President & Chief Accounting Officer | 1974 | – |
| Jared Freedberg | General Counsel & Corporate Secretary | 1969 | – |
| Jeff Boyle | Vice President of Investor Relations | – | – |
| Kelly Page | Senior Vice President & Global Head of Oncology Strategy and Program Leadership | – | – |
| Paul McInulty | Senior Vice President of Regulatory Affairs | – | – |
| Steve Weiss | Senior Vice President & Chief Human Resources Officer | 1970 | – |